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Critical Review

Alcohol Toxicity in Diabetes and Its Complications: A
Double Trouble?
Srikar Munukutla, Guodong Pan, Mandar Deshpande, Rajarajan A. Thandavarayan,
Prasanna Krishnamurthy, and Suresh S. Palaniyandi

Background: Eight percent of the U.S. population has been diagnosed with diabetes mellitus (DM),
while another large percentage has gone undiagnosed. As the epidemiology of this disease constitutes a
larger percentage of the American population, another factor presents a dangerous dilemma that can
exacerbate the hazardous eﬀects imposed by DM. Excessive alcohol consumption concerns the health
of more than 50% of all adults. When this heavy-alcohol-drinking population overlaps with DM and
its complications, the eﬀects can be dangerous. In this review, we term it as “double trouble.”
Methods: We provide evidence of alcohol-induced exacerbation of organ damage in diabetic conditions. In certain cases, we have explained how diabetes and alcohol induce similar pathological eﬀects.
Results: Known exacerbated complications include those related to heart diseases, liver damage,
kidney dysfunction, as well as retinal and neurological impairment. Often, pathophysiological damage
concludes with end-stage disorders and even mortality. The metabolic, cell signaling, and pathophysiological changes associated with “double trouble” would lead to the identiﬁcation of novel therapeutic
targets.
Conclusions: This review summarizes the epidemiology, diagnosis, pathophysiology, metabolic, and
cell signaling alterations and ﬁnally brushes upon issues and strategies to manage the “double trouble.”
Key Words: Diabetes Mellitus, Alcohol Toxicity, Epidemiology, Pathophysiology, Cell Signaling,
Aldehyde Dehydrogenase, Mitochondrial Dysfunction.
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ERY RECENTLY, IT has been predicted that approximately half of the U.S. population will suﬀer from diabetes or prediabetes in 2020 if the modern lifestyle continues
as present (United Health Group, 2010). The majority of the
patients will have type 2 diabetes, which itself is associated
with poor lifestyle choices, including an unhealthy diet constituting of high fat intake, high carbohydrate intake, as well
as increased inactivity due to high electronics usage and limited exercise. In this review, we are going to address another
layer of lifestyle-mediated hazardous eﬀects on diabetic
patients: alcohol toxicity. As heavy alcohol consumption is
also associated with poor eating habits and reduced exercise,

From the Division of Hypertension and Vascular Research (SM, GP,
MD, SSP), Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan; Department of Cardiovascular Sciences (RAT,
PK), Center for Cardiovascular Regeneration, Houston Methodist
Research Institute, Houston, Texas; and Department of Physiology
(SSP), Wayne State University, Detroit, Michigan.
Received for publication October 22, 2015; accepted January 11, 2016.
Reprint requests: Suresh S. Palaniyandi, PhD, Division of Hypertension and Vascular Research, Department of Internal Medicine, Henry
Ford Health System, Education and Research Building, Room 7044, 2799
West Grand Boulevard, Detroit, MI 48202; Tel.: 313-916-7055; Fax:
313-916-8759; E-mail: spalani2@hfhs.org
Copyright © 2016 by the Research Society on Alcoholism.
DOI: 10.1111/acer.13008
686

this may lead to diabetes or exacerbate diabetes-induced
complications. Before addressing pathophysiological conditions associated with such complications, it is important to
evaluate the clinical issues associated with alcoholic diabetics. Heavy drinkers, as well as moderate drinkers, consistently exhibit faulty obedience toward their selftreatment (Chew et al., 2005). This behavior includes the
inability to follow insulin treatments, lack of regard for dietary choices, negligence toward medication regimens, and
even inadequacy of visits to healthcare professionals (Chew
et al., 2005; Cox et al., 1996; Howard et al., 2004; Karter
et al., 2000).
At the metabolic level, oxidative stress is the major contributor of the pathogenesis of diabetic complications
(Brownlee, 2005). In our laboratory, we study the toxic
eﬀects of the secondary products of oxidative stress known
as reactive aldehydes, one being 4-hydroxy-2-nonenal
(4HNE) (Mali and Palaniyandi, 2014; Mali et al., 2014).
4HNE is detoxiﬁed by aldehyde dehydrogenases (ALDH)
(Vasiliou et al., 2000). In diabetic tissue, ALDH activity is
decreased (Hamblin et al., 2007; Mali et al., 2014; Palaniyandi et al., 2010; Wang et al., 2011), which in turn jeopardizes the metabolism of reactive aldehydes and leads to the
accumulation of more aldehydes. On the other hand, alcohol
toxicity results in increased accumulation of acetaldehyde
(Doser et al., 2009), a metabolite of ethanol (EtOH).
Alcohol Clin Exp Res, Vol 40, No 4, 2016: pp 686–697
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Incidentally, acetaldehyde is metabolized by ALDH itself
(Doser et al., 2009). Therefore, in diabetics with alcohol
intoxication, the diabetes-induced decrease in ALDH2 activity might lead to further accumulation of acetaldehyde and
other reactive aldehydes like 4HNE. Due to this, the risk of
health deterioration is 2-fold, caused by both an increased
prevalence of acetaldehyde, as well as the lowered activity of
ALDH2. The former can induce symptoms such as palpitation, hypotension, and nausea. The latter, when in reduced
levels in the diabetic heart, leads to mitochondrial dysfunction instigated by increased 4HNE adduct formation on
mitochondrial complex proteins.
Collectively, this diabetes mellitus (DM)-induced and
alcohol-induced insulin resistance and mitochondrial dysfunction are integral in developing complications such as
cardiomyopathy. Additionally, it appears both diabetes
and alcohol intoxication potentiate one another’s adversity at the level of nutrition, metabolism, and pathophysiology. Recently, a study performed by Gardebjer and
colleagues (2015) showed that regular alcohol drinking in
pregnant rats resulted in lowered insulin sensitivity, as
well as decreased glucose tolerance in aﬄicted fetuses.
Furthermore, when these fetuses were given diets high in
fat and cholesterol, the diabetes-related symptoms were
compounded (Gardebjer et al., 2015). Often undermined
by healthcare professionals, alcohol toxicity is a major
component in inducing and exacerbating DM-related
symptoms. This review will focus on the epidemiology,
pathophysiology, metabolic signaling, and management
strategies of the deleterious eﬀects of heavy alcohol drinking in diabetes.

EPIDEMIOLOGY OF DIABETICS WITH ALCOHOLDRINKING ISSUES
Diabetes and Alcohol-Drinking Issues in the General Public
In 2014, a staggering 29.1 million people were found to
suﬀer from DM in the United States (CDC, 2014). Exacerbating this epidemic, 27.8% or 8.1 million people that had
DM actually went undiagnosed (CDC, 2014). The total
aﬄicted DM population in the United States primarily is
encased within the “adult” population, as 28.9 million people who are 20 years or older suﬀer from the epidemic
(99.3% of all diabetics) (CDC, 2014). Furthermore, after
accounting for the entire adult population, it can be determined that 12.3% of all people aged 20 or older have DM
(CDC, 2014). By 2050, however, it is predicted that 33% of
the U.S. population will have DM (CDC, 2010). Around
87% of adults (aged 18 or older) in 2013 admitted to drinking alcohol at least once during their life (NIH-NIAAA,
2013). Furthermore, around 56% of this same adult population admitted to drinking in the previous month (NIHNIAAA, 2013). With these 2 large separate populations that
drink alcohol and suﬀer from DM, many overlaps can be
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common. Unfortunately, in this speciﬁc population of people
that are both diabetic and alcohol drinking, many healthrelated issues can arise.
While moderate drinking has been proven to show a positive eﬀect on DM and its associated complications (Baliunas
et al., 2009; Carlsson et al., 2003; Tanasescu et al., 2001;
Wei et al., 2000), more strenuous drinking has been associated with pathophysiology (Baliunas et al., 2009; Beulens
et al., 2008; Blomster et al., 2014; Carlsson et al., 2003; Pitsavos et al., 2005; Tanasescu et al., 2001; Wei et al., 2000).
This pattern of abusive drinking is not uncommon after all,
as 24.6% of adults admitted to binge drink in the preceding
month in the United States (NIH-NIAAA, 2013). Furthermore, chronic alcohol addiction is also a grave problem.
Around 6.6% of all alcohol drinkers in the United States,
equating to about 17.3 million people, are alcohol abusers
who have extreme drinking habits (SAMHSA, 2014). If the
present scenario continues, the risk for deleterious eﬀects is
exacerbated as a result of this double trouble (alcohol and
DM) (Fig. 1).
Heightened Risk of Diabetes Caused by Excessive Alcohol
Intake
Diﬀerentiating Type 1 and Type 2 DM. Type 1 DM is
insulin-dependent DM (insulin deﬁciency). It is usually diagnosed in young people in their childhood or adolescence. It is
triggered by the autoimmune destruction of the insulinproducing beta cells of the islets of Langerhans in the pancreas. Factors such as contact with viruses, dietary quality of
early lifestyle, and vitamin D deﬁciency can cause the disease;
however, genetics is one of the main culprits (MacNaught
and Holt, 2015). Often, type 1 DM leads to impaired glucose
handling due to lack of insulin, and subsequently
hyperglycemia.
Type 2 DM is noninsulin-dependent DM (insulin resistance). It is characterized as a disease mostly originating in
the adult period of a person’s life, as one’s lifestyle slowly
reduces the sensitivity of the insulin, causing hyperglycemia.
In many cases, it may be accompanied with hypertension,
increased low-density lipoprotein (LDL), lowered high-density lipoprotein (HDL), hyperlipidemia, and obesity, which
is collectively known as metabolic syndrome (Huang, 2009).
Among the diabetics, the type 2 DM patients are usually
above the legal age of alcohol drinking, unlike most juvenile
type 1 DM patients. Therefore, in many cases, this prevents
alcohol-induced complications from arising in type 1 DM
patients. Almost 90 to 95% of diabetics have type 2 DM,
leaving behind only 5 to 10% of type 1 DM patients (American Diabetes Association, 2009). Nevertheless, even among
type 1 DM patients, limiting alcohol-induced exacerbation
of diabetes and associated complications would improve
quality of life. Therefore, in this review, we will provide evidence available from both type 1 and type 2 diabetic studies,
presumably more related to type 2 DM.
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Fig. 1. Epidemiology of “double trouble.” The extent of health risk for diabetics upon alcohol consumption in U.S. adult populations is shown.

Alcohol’s Collective Eﬀects on DM. Numerous studies
have pointed out the protective eﬀect of moderate alcohol
intake in reducing the prospect of type 2 DM (Baliunas
et al., 2009; Carlsson et al., 2003; Wei et al., 2000). Speciﬁcally, a meta-analysis taking into account past studies suggested that a maximum daily intake of 22 g of alcohol in
men and 24 g of alcohol in women will abate the risk of type
2 DM (Baliunas et al., 2009). If moderate amounts are consumed, there could be a 30 to 40% decrease in the risk for
DM both in women and in men (Carlsson et al., 2003). This
reduction can be clearly seen in the U-shaped graph comparing alcohol intake and hazard of DM that many analyses
have yielded (Baliunas et al., 2009). Despite this positive outlook on alcohol consumption on DM, a very strong negative
attribution still exists. When women ingested more than 50 g
of alcohol and men around 60 g of alcohol, the protective
eﬀect of alcohol vanished, and instead, an increased risk for
DM was apparent (Baliunas et al., 2009). These amounts
correlate to about 2 drinks every day (Baliunas et al., 2009).
Furthermore, Kao and colleagues (2001) quantiﬁed this risk
of DM due to excessive alcohol intake. It was determined
that men who consumed more than 21 drinks a week had
50% increase in risk than similar men who consumed no
more than 1 drink a week (Kao et al., 2001). Other studies
point out a similar adverse aﬀect. Wei and colleagues (2000)
concluded that when comparing moderate and excessive
alcohol drinkers, a 2-fold escalation in the risk of DM was
found in the excessive drinking group. As per these studies,
the prospect of single trouble (alcohol) leading to double trouble could be alarming.

We are more interested in the eﬀects of alcohol on diabetes-induced complications than diabetes itself. In particular, we are interested in diabetic cardiac complications as
more than 60% of type 2 diabetics and more than 40% of
type 1 diabetics die of heart diseases (de Ferranti et al., 2014;
Laakso, 2010). Therefore, in our review, we will highlight the
eﬀects of alcohol on diabetic complications with a heavier
emphasis on cardiac complications.
Diabetic Complications Associated with Alcohol Intake
Diabetic Heart Diseases. Diabetics have a 1.7-, 1.8-, and
1.5-fold increase in the risk for cardiomyopathy-induced
mortality, heart attacks, and strokes, respectively, compared
to nondiabetics (CDC, 2014). While moderate drinking has
been shown to lower cardiovascular complications in people
with DM, excessive drinking has also been shown to reverse
the positive eﬀect (Blomster et al., 2014). A J-shaped graph
is obtained when comparing the amount of EtOH consumed
against the risk of cardiovascular disease (Pitsavos et al.,
2005). While initially, there is a beneﬁcial eﬀect, after a
threshold of 12 g of EtOH consumed, the risk of cardiovascular disease increases by 47% (Pitsavos et al., 2005). The
risk for acute events is also heightened, as men who consumed more than 21 drinks a week and women who consumed more than 14 drinks a week (heavy drinkers)
experienced an increased risk for cardiovascular events,
microvascular events, and even death (Blomster et al., 2014).
In diabetics who drank 12 to 24 g of alcohol daily, the
risk of total acute coronary syndromes increased more than
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5 fold compared to those who drank a limited amount
(<12 g daily) (Pitsavos et al., 2005). When this limited group
was compared to extreme drinkers (more than 24 g daily),
the risk escalated by more than 10-fold (Pitsavos et al.,
2005). Furthermore, when examining myocardial infarction
rates, the risk increased by almost 8-fold in heavy drinkers
(more than 24 g daily) compared to a limited alcohol consuming group (<12 g daily) (Pitsavos et al., 2005). In terms
of unstable angina, the risk grew by more than 13-fold in
heavy drinkers (more than 24 g daily) compared to limited
drinkers (<12 g daily) (Pitsavos et al., 2005). These dramatic
increases in cardiovascular risks serve to prove the reoccurring J-shaped relationship that exists between alcohol consumption and acute cardiac events.
Taken together, the potentiation of cardiac diseases in diabetes with alcohol toxicity will be multifold.
Diabetic Nephropathy. DM-induced neph-ropathy is a
major reason for kidney failure (CDC, 2014). In 2011,
around 44% of all cases involving kidney deterioration were
related to DM in the United States (CDC, 2014). In the same
year, almost 230,000 diabetics underwent dialysis or even
transplantation to treat DM-induced kidney failure (CDC,
2014).
In patients with DM or obesity, the risk of nonalcoholic
fatty liver (NAFL) escalates by 60 to 90% (Targher et al.,
2012). Additionally, with the addition of new studies, it is
now suggested that those with NAFL, problematically, are
now in greater danger of developing chronic kidney disease
(Targher et al., 2012). Alcohol intake, when kept to moderation, has been shown to lower the risk of renal cell carcinoma; however, excessive amounts have been linked to
numerous complications, including postinfectious glomerulonephritis, immunoglobulin A nephropathy, kidney graft
failure, acute kidney injury, renal papillary necrosis, as well
as the deadly end-stage renal disease (ESRD) (Perneger
et al., 1999; Schaeﬀner and Ritz, 2012). In a recent study,
Perneger and colleagues (1999) found that the consumption
of more than 2 drinks daily can increase the risk of ESRD by
4-fold. Furthermore, it was also found that limiting this habit
of 2 drinks daily can minimize the total diagnoses of ESRD
by 9% in the diabetic population (Perneger et al., 1999).
Patients who simultaneously suﬀer from DM and consume
excessive alcohol can experience disastrous eﬀects on the kidneys, both directly, and indirectly.
Diabetic Hepatopathy. Liver disease is the fourth leading
cause of death in type 2 diabetic patients (de Marco et al.,
1999). For instance, liver cirrhosis accounted for 5 to 12% of
diabetes-related deaths (de Marco et al., 1999). Diabetic liver
diseases comprise of abnormal liver enzymes, nonalcoholic
fatty liver disease (NAFLD), cirrhosis, hepatocellular carcinoma, and acute liver failure (Diehl and Choi, 2008; El-Serag
et al., 2004). Patients with diabetes have a high prevalence of
liver disease, and on the other hand, patients with liver disease or alcoholic liver disease have a high prevalence of dia-
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betes (Tolman et al., 2007). NAFLD is found in many obese
patients with a wide spectrum of diseases associated with
metabolic syndrome, including type 2 DM (Diehl and Choi,
2008). In particular, in patients with type 2 DM, NAFLD
can result in nonalcoholic steatohepatitis (NASH), which is
shown to greatly increase the risk of complex cirrhosis and
even death (Chandrasekaran et al., 2012; Diehl and Choi,
2008). Diehl and Choi (2008) reported that NASH can
increase the occurrence of cirrhosis in obese people (with
type 2 DM) by 75 times. This is especially concerning, as
87% of diabetics with NAFLD also had NASH (Diehl and
Choi, 2008).
Alcohol-related cirrhosis constitutes a major proportion
of all cirrhosis-related mortalities in the United States (NIHNIAAA, 2013). Around 48.0% of all cirrhosis-related deaths
were caused by excessive alcohol consumption (NIHNIAAA, 2013). In the population of people aged 25 to 34, a
staggering 72.7% of all cirrhosis diagnoses were related to
alcohol (NIH-NIAAA, 2013). When type 2 diabetics consume alcohol, an altogether synergized risk of cirrhosis is
prevalent. As type 2 DM progresses, NASH and alcoholinduced cirrhosis can become a formidable toxic combination.
Diabetic Neuropathy. Frequently, diabetic neuropathy
results in nerve pain in the legs (Fowler, 2008). In certain
extreme cases, numbness associated with the nerve damage
can lead to negligence in noticing scrapes or ulcers (Fowler,
2008). These problems can lead to serious infections, which
may then have to be treated with amputations (Fowler,
2008). In 2010, DM alone caused around 60% of all pathological, nonacute lower body amputations (CDC, 2014).
Several studies have shown that consuming alcohol while
suﬀering from DM can lead to an enhanced risk of neuropathy (Emanuele et al., 1998). McCulloch and colleagues
(1980) reported that diabetic men who had 3 to 4 drinks daily
had a higher risk of developing diabetic neuropathy and its
associated nerve pain than diabetics who had fewer drinks.
Later, Mitchell and Vinik (1987) accentuated these results by
proving that diabetics who ingested at least 8 drinks weekly
more rapidly acquired the symptoms of neuropathy than diabetics who drank a lesser amount of alcohol.
Diabetic Retinopathy. Another common diabetic complication, retinopathy is found in around 25.8% of all diabetics
(CDC, 2014). With damaged blood vessels in the retinal area,
diabetic retinopathy can lead to vision defects (CDC, 2014).
In more severe cases, such as in the rare 4.4% of diabetics,
progressive diabetic retinopathy can bring upon advanced
macular edema and even complete loss of vision (CDC,
2014).
In a clinical investigation, it was found that diabetics who
did not suﬀer from retinopathy initially were found to possess a greater chance in acquiring the disease if they drank at
least 10 pints of beer weekly (Young et al., 1984). Nondrinking diabetics exhibited an opposite result, as the risk for
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retinopathy was much lower (Young et al., 1984). Furthermore, these ﬁndings were accentuated by Kohner and colleagues (1998) through the United Kingdom Prospective
Diabetes Study, which revealed that alcohol-drinking diabetic men had more cases of diabetic retinopathy than alcohol abstaining diabetics.
ISSUES IN DIAGNOSING AND TREATING DIABETICS
WITH HEAVY-ALCOHOL-DRINKING PROBLEMS
Drinking issues are usually not diagnosed accurately.
Most of the time, the amount of alcohol consumption is selfreported and most drinking habits are sporadic. Therefore, it
is diﬃcult to diagnose and treat diabetics who are heavy drinkers.
Acknowledging the Patient’s Chronic Drinking Issues
In a recent case study conducted by Alromaihi and colleagues (2012), an aged female type 2 diabetic (named S.E.),
who was undergoing therapy using metformin and glipizide,
was admitted into a hospital for a routine health checkup.
As an obese female with near hypertension, she had a hazardous A1c of 11% (Alromaihi et al., 2012). Also, with
increased cholesterol, heightened triglycerides, low HDL,
and high LDL, many symptoms of metabolic syndrome were
apparent (Alromaihi et al., 2012). When asked about alcohol
intake, she reported about 360 g of alcohol intake daily
through mainly spirits (Alromaihi et al., 2012). Despite
encouragement from her caretakers, she refused to reduce
intake of alcohol or even seek help for her excessive drinking
habits (Alromaihi et al., 2012).
The prevalence of such patients, especially in the United
States, is unexpectedly high. Throughout their past, diabetic
alcoholics may have consumed large amounts of alcohol and
will continue to do so, even if strongly advised to reconsider.
As patients’ unhealthy choices continue to exacerbate DM, it
is not uncommon to see a near-fatal event occur. In this
speciﬁc case study, the excessive alcohol led to esophageal
varices, and subsequently gastrointestinal bleeding, which
altogether led S.E. to completely stop alcohol consumption
(Alromaihi et al., 2012). When events like this occur, it is the
healthcare provider’s job to encourage and motivate patients
to acquire habits and changes of thought that will accommodate their own medical situations, otherwise, repeated experiences can turn deadly.
The Risk of Hypoglycemia in the Diabetic Alcoholics
Excessive alcohol consumption in the diabetic can pose
serious problems. A general study showed that around 17%
of all the cases of hypoglycemic events in diabetics were
caused by alcohol consumption alone (Engler et al., 2013;
Pedersen-Bjergaard et al., 2005).
In the case of S.E., the primary concern of the healthcare
provider is to dramatically lower the A1c to a safe level using

insulin therapy, while making sure that the risk of hypoglycemia is low. Having unsteady treatments of insulin combined with chaotic scheduling can only exacerbate the
patient’s condition and cause hypoglycemia.
Heavy alcohol drinking may deteriorate the levels of
plasma glucose. This in turn can cause overdischarge of insulin, which may dangerously lower glucose in the blood (resulting in hypoglycemia) (Alromaihi et al., 2012). In other
cases, hepatic gluconeogenesis may become diminished,
which can also lead to hypoglycemia (Alromaihi et al.,
2012). In many cases, while the risk of hypoglycemia is certainly alarming, the rise in A1c levels over time represents a
greater danger.
PATHOPHYSIOLOGY OF DOUBLE TROUBLE IN ENDORGAN DAMAGE
As of now, there are no clinical or preclinical research
studies on end-organ damage in alcohol consumption in the
diabetic condition. Hence, we strategized to present evidence
either from diabetic complications or alcohol abuse-induced
organ damage.
Diabetic Cardiomyopathy
During DM, the heart undergoes various, yet substantial
structural and functional changes. A clear structural change
can be apparent in left ventricular hypertrophy (LVH),
derived through severe inﬂammation shown by the increased
prevalence of C-reactive protein (CRP) and ﬁbrinogen
(Hayat et al., 2004). LVH involves the expanding of the left
ventricle due to the increased stress of the heart to fulﬁll the
body’s requirements. As the size of the ventricle’s wall abnormally increases, contractions become more diﬃcult to execute, and the heart loses its circulatory ability. LVH is ﬁnally
diagnosed when the LV mass exceeds 125 g/cm3 in men and
110 g/cm3 in women (Hayat et al., 2004).
Systolic and diastolic functional deterioration is also common in patients with DM. Systolic deterioration can be seen
with a minimized LV ejection fraction, and diastolic decline
is evidenced by lowered rates of LV relaxation and diastolic
ﬁlling (Hayat et al., 2004). Additionally, aldosterone-associated ﬁbrosis may be caused by excessive generation of collagen, as well as a proliferated ﬁbroblast population (Brilla
and Weber, 1992; McEwan et al., 1998; Young et al., 1995).
This ﬁbrosis may occur in the perivascular and interstitial
areas of heart tissue (Factor et al., 1980). Furthermore, due
to dyslipidemia as well as hyperglycemia that occur simultaneously with type 2 DM, changes in the endothelium can be
prevalent (Hayat et al., 2004). Type 2 DM has been shown
to cause degradation of the capillary endothelium, disjoint
the intercellular junctions, and modify production of key glycoproteins attached to endothelial cells (Hayat et al., 2004;
Tooke, 1995). Also, it is well documented that patients with
endothelial alterations have an increased risk of developing
atherosclerosis as well as congestive heart failure after heart
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attacks due to the impaired ancillary circulation in the heart
(Hayat et al., 2004).
Alcohol-Exacerbated Eﬀects
A main component of further exacerbation of cardiac
function by alcohol can be seen through changes in cardiomyocyte function. Particularly, there are 2 pathophysiological transformations seen (Molina et al., 2014). A key
alteration is in mitochondrial function, seen when alcohol
inhibits glutathione, which allows for reduced function of
antioxidants, and thus increased oxidative stress aﬄiction
toward cardiomyocytes, and higher rates of apoptotic death
(Vendemiale et al., 2001). Next, aberrations in calcium signaling lead to an overexpression of the L-type calcium channel, which can stimulate calcium accumulation, and thus
exacerbate apoptosis and dysfunction in cardiomyocytes
(Guppy et al., 1995).
Furthermore, the progression of cardiac ﬁbrosis associated
with the intake of alcohol can lead to a series of pathophysiological changes. Cardiac ﬁbrosis caused by increased oxidative stress through the overaccumulation of collagen in the
cardiac tissue leads to impaired ventricular ﬁlling, diastolic
dysfunction, lowered LV ejection fraction, as well as LV dilation, all structural alterations to the heart (Molina et al.,
2014; Piano, 2002). Interestingly, these same complications
that accompany alcohol-induced cardiac ﬁbrosis are also
prevalent in DM-associated patients, further exacerbating
the remodeling of cardiac architecture and functional
disarray.
Diabetic Nephropathy
Due to DM-induced relaxation of glomerular arterioles,
an overall escalated rate of ﬁltration is seen (Zelmanovitz
et al., 2009). This can account toward an increased rate of
renal perfusion, especially dangerous as albumin can be
released to the glomerulus from the capillaries (Zelmanovitz
et al., 2009). In turn, the glomerular basement membrane is
enlarged and there is severe aﬄiction toward podocytes and
therefore defective glomerular function (Zelmanovitz et al.,
2009).
Additionally, in DM, a correlative high amount of CRP,
tumor necrosis factor (TNF)-a, as well as interleukins 1, 6,
and 28, can be recorded (Zelmanovitz et al., 2009). All of
these can be indicative of markers for severe inﬂammation
and are related to albuminuria as well as are key mechanisms
for development of ESRD (Zelmanovitz et al., 2009).
Alcohol-Exacerbated Eﬀects
In excessive alcohol consumption, the glomerular basement membrane becomes strikingly enlarged due to excessive
cell proliferation (Epstein, 1997); especially in kidney
tubules, damaged cells become expanded and structurally
transformed (Epstein, 1997). Thus, kidney swelling is preva-
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lent in heavy drinkers, resulting in incapacitation of key
nephron function (Epstein, 1997). This alcoholic-induced
nephromegaly further exacerbates similar structural alterations initiated by DM and therefore can result in severe
podocyte damage, as well as impaired glomerular function
(Epstein, 1997).
Diabetic Hepatopathy
The primary changes that occur in the liver in DM are
accentuated by the progression of fatty liver disease.
Throughout this process, 3 factors are crucial in determining the course: TNF-a, adiponectin, and fatty acids (Chaldakov et al., 2003; Klaus, 2004; Rajala and Scherer, 2003).
Free fatty acids (FFA) are present in the liver and fatty
tissue and often travel between the two (Diehl and Choi,
2008). Furthermore, they are especially important in the
production of TNF-a and adiponectin (Kershaw and Flier,
2004). Both of these mentioned cytokines are important in
regulating hepatocytes (which manage fat accumulation in
the liver) (Diehl and Choi, 2008). Adiponectin allows for
the reduction of lipids in the liver by lowering intake of
fatty acids and increasing dispensing and oxidation of fatty
acids (Diehl and Choi, 2008). It also increases the sensitiveness of insulin (Arner, 2003). However, TNF-a is an
antagonist toward adiponectin, helping to create steatosis
in hepatocytes and causing further desensitization of insulin (Chaldakov et al., 2003). Additionally, when TNF-a
levels are superior to adiponectin’s presence, this increases
production of reactive oxygen species (ROS), enlists
inﬂammatory conditions in the liver, as well as causes
apoptosis of hepatocytes, which can cause steatohepatitis
(Diehl and Choi, 2008; Pessayre et al., 2002). In further
studies, these same comparative levels have been proven to
cause NASH, a deadly and fatal liver disease (Hui et al.,
2004).
Alcohol-Exacerbated Eﬀects
By disrupting mitochondrial pathways, alcohol inhibits
oxidation of FFA, which leads to their accumulation in the
liver (Baraona and Lieber, 1979). Over time, lipotoxicity can
be triggered due to abnormal levels of FFA and triglycerides
and can lead to steatosis and apoptosis (Molina et al., 2014).
Considering the fatty liver that already presents itself in DM,
alcohol would further exacerbate this condition and in
essence, can increase the risk of developing conditions such
as steatosis. Furthermore, other pathophysiological changes
induced by alcohol include promotion of inﬂammatory cells
in the liver, overexpression of inﬂammation-inducing cytokines, creation of ROS, as well as oxidative stress from cellular
damage in the liver (Gao and Bataller, 2011). All of these factors have been shown to increase the risk of steatohepatitis in
heavy drinkers (Gao and Bataller, 2011). Unfortunately, in
DM-associated patients, these inﬂammation-characterized
conditions can be further exacerbated, leading to increased
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risks for conditions such as steatohepatitis and cirrhosis,
dangerous end-stage liver damage (Molina et al., 2014).
Hepatocyte damage is another mainstay of chronic alcohol usage. Acetaldehyde, a metabolite of alcohol metabolism, has been shown to mitigate functional processes in
hepatocytes, increase oxidative stress, and exacerbate fat peroxidation (Setshedi et al., 2010). It may also target key proteins like collagen, which can lead to additional toxic adduct
synthesis (Casini et al., 1991). In DM, this is especially hazardous, as hepatocytes are already aﬄicted by the inﬂammatory and ROS-induced conditions created by TNF-a and
adiponectin (Diehl and Choi, 2008).
Diabetic Retinopathy
Diabetic retinopathy is mainly associated with the
increased activity of aldose reductase in creating alterations
in the polyol pathway, which changes glucose into glucose
alcohol (Fowler, 2008). Due to hyperglycemia associated
with DM, increased activity with the pathway results in sorbitol-exacerbated osmotic stress (Fowler, 2008). This key
development can cause creation of microaneurysms, enlargement of inner layer membranes, and pericyte damage, all
devastating to the health of the eye (Fowler, 2008).
Additionally, increased activity of vascular endothelial
growth factor and growth factor beta (prevalent in DM)
plays important roles in progressing retinopathy (Fong
et al., 2004; Fowler, 2008). With these cases, retinopathy is
reported as background retinopathy and/or proliferative
retinopathy (Fowler, 2008). Background retinopathy entails
retinal bleeding in the shape of small circles, formation of
rough exudates, edema, and as mentioned previously,
microaneurysms, whereas proliferative retinopathy includes
vitreous hemorrhage caused by overproduction of blood vessels on the retina, as well as partial or complete blindness in
the progressed pathological stage (Fowler, 2008).
Alcohol-Exacerbated Eﬀects
A main complication of alcohol-induced eye disease is central serous retinopathy (CSR). It mainly involves the removal
of the retinal pigment epithelium from the eye tissue, occurring through many unique methods such as bullous, multifocal, bilateral, and extrafoveal removal (Gkotsi et al., 2013).
Supportively, recent studies such as the one by Haimovici
and colleagues (1997) have shown a causative relationship
between alcohol consumption and intensity of CSR. In other
cases, alcohol has been known to exacerbate hemorrhage
occurrences and exudate formation, especially troublesome
as these are the very conditions that already exist in DM
(Abe et al., 1995). Additionally, alcohol has been known to
cause abnormal transudation of ﬂuid, resulting in blockages
in the capillaries and venous areas (Prunte and Flammer,
1996). This is also concerning, due to the proliferative and
enlarging themes of retinopathy seen in DM. Furthermore,
oxidative stress caused by alcoholism can cause the nitration

of tyrosine in cellular proteins, which can deteriorate the
eﬀectiveness of the outer blood–retina barrier, increasing the
risk of harmful substances advancing to the delicate retinal
areas (Haussinger and Schliess, 2008; Murthy et al., 2001).
Diabetic Neuropathy
Neuropathy in patients with DM is usually associated with
the intensity of hyperglycemia (Fowler, 2008). Nevertheless,
any hyperglycemic state will allow for the 3 main mechanisms that induce neuropathy: slowed rheological function,
oxidative stress, and polyol aggregation (Fowler, 2008). In
the hyperglycemic state, blood ﬂow through nerves is lowered and there is greater endothelial vascular pressure (Miranda-Massari et al., 2011; Tooke, 1996). Key compounds
such as myoinositol are also lost, which adds to the rheological damage (Miranda-Massari et al., 2011). With oxidative
stress, increased activity of protein kinase C alters key metabolic pathways, which can cause defective axoplasmic transport as well as vascular aﬄiction (Inoguchi et al., 2003;
Miranda-Massari et al., 2011).
Also, an increase in aldose reductase activation allows for
aggregation of sorbitol (through the glucose to sorbitol pathway) and thus causes damaging glycosylation of key proteins
needed in the peripheral nervous system (Miranda-Massari
et al., 2011).
The most prevalent type of neuropathy is chronic sensor
motor distal symmetric polyneuropathy, which essentially
results in loss of sensation to touch, temperature, and vibration (Bansal et al., 2006; Fowler, 2008). This type of neuropathy is also associated with a needle-like pain that occurs
in many patients (Bansal et al., 2006; Fowler, 2008). Another
common type of neuropathy is DM-induced autonomic neuropathy (Bansal et al., 2006; Fowler, 2008). This entails
many serious conditions such as gastroparesis, digestive
problems, tachycardia, bladder failure, anhidrosis, silent
ischemia, and erectile dysfunction (Bansal et al., 2006; Fowler, 2008). Autonomic neuropathy is also known for its burdensome amount of mortality (Fowler, 2008).
Alcohol-Exacerbated Eﬀects
Alcohol-induced neuropathy is mainly caused by the
weakening of axons and thinning of the myelin sheath covering nerve ﬁbers. In any case, alcohol, other than altering
transport of axons and agitating cytoskeletal structure, has
been proven to increase oxidative stress, by diminishing
antioxidant concentrations, creating new ROS, as well as
promoting fat peroxidation (Montoliu et al., 1994). The created ROS products cause free radical damage to alreadydamaged nerves in DM, exacerbating the neuropathy
(McDonough, 2003). Furthermore, alcohol can also induce
neuropathy through its metabolite acetaldehyde (Chopra
and Tiwari, 2012). Unlike EtOH, acetaldehyde directly represents a neurotoxic hazard, through its abilities to impair
spinal cord function and disturb key neuronal organelles

ALCOHOLISM IN DIABETES

693

(Goodlett and Horn, 2001). The pathological changes in
multiple organ systems are summarized in Table 1.
CELL SIGNALING ABERRATIONS IN ALCOHOL
INTOXICATION AND DIABETES
The major cell signaling changes associated with diabetes
are those related to oxidative stress, mitochondrial dysfunction, glucose auto oxidation and advanced glycated end
products (AGE), aberrant protein kinase C signaling, reninangiotensin-aldosterone system (RAAS) activation, abnormal lipid/fatty acid metabolism, aldehydic stress, and impairment of ALDH2, as well as inﬂammation. There are a lot of
reviews that detail key signaling changes in diabetic complications of multiple organs such as the heart (Brownlee, 2005;
Reusch, 2003), liver (Garcia-Compean et al., 2009), kidney
(Reidy et al., 2014), eye (Ciulla et al., 2003), and peripheral
nervous system (Yagihashi et al., 2011). The cell signaling
changes with long-term alcohol abuse or binge drinking
result in detrimental consequences to the organs. Similar to
DM-induced complications, many reviews that address cell
signaling changes and mechanisms in the heart (Guzzo-Merello et al., 2014; Piano and Phillips, 2014), liver (Williams
et al., 2014), and other organs (Jung et al., 2011) can be
referred for individual organ damage with alcohol toxicity.
Broadly, these changes are oxidative stress-induced abnormal signaling, mitochondrial dysfunction and impaired

Table 1. Pathophysiological Effects of Alcohol and Diabetes on Organs
Organ

Diabetes

Heart

Diastolic dysfunction
LV hypertrophy
Fibrosis
Atherosclerosis
Myocardial infarction
Impaired glomerular
apparatus
Microalbuminuria
Macroalbuminuria
End-stage renal disease
Fatty liver disease
ROS-induced inflammation
Steatosis
NASH
Microaneurysms
Pericyte damage
Rough exudate formation
Edema
Vitreous hemorrhage
Chronic sensor motor
distal symmetric
polyneuropathy
Gastroparesis
Tachycardia
Bladder failure
Anhidrosis
Silent ischemia
Erectile dysfunction

Kidney

Liver

Eyes

Peripheral
nervous
system

Alcohol
Contractile dysfunction
LV dilation
Fibrosis
Myocardial infarction
Nephromegaly
Impaired fluid handling
Electrolyte disturbances
Hepato-renal disease
Steatosis
Steatohepatitis
Cirrhosis
NASH
Vitreous hemorrhage
Rough exudate formation
Impaired blood–retina barrier
ROS-induced oxidative stress
Impaired spinal cord function

LV, left ventricular; NASH, nonalcoholic steatohepatitis; ROS, reactive
oxygen species.

bioenergetics, calcium overload and abnormality, aldehydic
(carbonyl) stress and ALDH2 inactivity, activation of
RAAS, and cytokine signaling changes with inﬂammation.
As our laboratory is interested in the aspects of oxidative
stress-induced reactive aldehyde toxicity and ALDH2
impairment, we will discuss this topic and mitochondrial dysfunction in both alcohol toxicity and diabetic complications.
We will also highlight key aspects of cell signaling changes in
terms of cardiac pathology only.
ALDEHYDE STRESS AND ALDH2 IMPAIRMENT IN
DIABETES AND ALCOHOL TOXICITY
Diabetes-induced hyperglycemia leads to ROS generation (Brownlee, 2005). Upon lipid peroxidation of polyunsaturated fatty acids in biological membranes, reactive
aldehydes such as 4HNE are generated (Mali and Palaniyandi, 2014). These secondary products of oxidative
stress can form adducts with proteins and DNA which
can result in cellular dysfunction (Mali and Palaniyandi,
2014). Another source of reactive aldehydes (carbonyl
stress) in diabetes is caused by glucose toxicity due to
excessive cellular glucose (Jaganjac et al., 2013). This is
manifested as glucose autoxidation, protein kinase C activation by production of diacyl glycerol, methylglyoxal
formation and glycation, hexosamine metabolism, sorbitol
formation, and changes in oxidative phosphorylation
(Brownlee, 2005). Most importantly, the metabolic products of such anomalous glucose metabolism lead to generation of AGE and other glucose-derived carbonyl
compounds which have long-lasting detrimental impacts
on cellular function (Singh et al., 2014). For instance,
4HNE forms adducts on mitochondrial complex proteins
(Lashin et al., 2006), proteasome subunits (Farout et al.,
2006), and alters cellular functions (Dubinina and Dadali,
2010). When 4HNE was incubated with cardiomyocytes,
it increased protein adducts and attenuated mitochondrial
respiration (Hill et al., 2009). 4HNE and other aldehydes
are detoxiﬁed by ALDH isozymes, glutathiones, and
aldose reductase. ALDH2, a cardiac mitochondrial
enzyme, levels and activity are reduced in the diabetic
heart, accompanied by an increase in 4HNE protein
adducts (Hamblin et al., 2007; Palaniyandi et al., 2010;
Wang et al., 2011; Zhang et al., 2012). ALDH2 overexpression (Zhang et al., 2012) and activation of ALDH2
by Alda-1 (Palaniyandi et al., 2010), a pharmacological
agonist of ALDH2, attenuated diabetic cardiac dysfunction and remodeling by reducing 4HNE adduct formation. In cultured cardiomyocytes, 4HNE was shown to
reduce mitochondrial respiratory reserve capacity by
forming protein adducts dose dependently (Hill et al.,
2009). We have recently shown 4HNE or ALDH2 inhibition reduces mitochondrial respiration and reserve capacity in cultured cardiomyocytes (Mali et al., 2016).
However, the overexpression of ALDH2 attenuated mitochondrial damage in streptozotocin-injected diabetic
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hearts (Zhang et al., 2012). ALDH2 activation by Alda-1,
an agonist of ALDH2 conferred cardio-protection against
experimental diabetes by improving mitochondrial function with reduced 4HNE adduct formation (G. Pan,
unpublished data).
Ren and Wold (2008) have summarized the EtOH- and
acetaldehyde-induced cardiotoxicity and cardiac dysfunction
in periodic reviews (Zhang and Ren, 2011; Zhang et al.,
2004). Increased acetaldehyde can form adducts with proteins and damage cellular function (Nakamura et al., 2000;
Setshedi et al., 2010; Worrall et al., 2000). Upon EtOH consumption, ALDH2 converts acetaldehyde into acetic acid
and eliminates it from the body. Therefore, overexpression
of ALDH2 reduces the pathology of alcoholic cardiomyopathy (Doser et al., 2009). Conversely, ALDH2*2, a mutant
form of ALDH2 with low activity, increases the toxic eﬀects
of alcohol consumption (Zhang and Ren, 2011). It has
noticeable negative eﬀects in East Asians with this mutation
(Nakamura et al., 2002). In clinical observations, ALDH2
mutation is associated with increased propensity to develop
diabetic complications (Suzuki et al., 2004). In our ongoing
studies, we found acute diabetes reduces mitochondrial respiration in ALDH2*2 mutant mice (Pan et al., 2015). The
worst scenario is when diabetics increase alcohol consumption to toxic levels chronically. At this point, chronic hyperglycemia increases 4HNE adduct and decreases ALDH2
activity. Additionally, if diabetics drink alcohol excessively,
this will lead to increased accumulation of acetaldehyde due
to reduced ALDH2 activity.
There are no studies that have explored the consequences
of excessive acetaldehyde and 4HNE-like reactive aldehydes
with impaired ALDH2 activity. As ALDH activity is based
on the availability of substrates (aldehydes) and cofactor
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(nicotinamide adenine dinucleotide), it will be very useful to
carry out studies that investigate eﬀects of diﬀerent aldehydes on each other’s metabolism and overall cellular function
and metabolism.
ISSUES AND STRATEGIES TO COMBAT THE “DOUBLE
TROUBLE”
In this section, we will provide our views on issues and
then ideas to resolve them. First, the recognition of “double
trouble” is very vital for management. It is crucial to investigate the change associated with the precedence of diabetes or
alcohol intoxication on one another. Let us say if a patient is
type 1 diabetic, the onset of diabetes may precede alcohol
intoxication in the majority of cases. Because type 1 DM is a
juvenile disease, it may be possible that by the time aﬄicted
patients reach middle age, they may have already experienced a few decades of hyperglycemia. The onset of diabetic
complications may start around this time, near a period of
heavy drinking. On the other hand, if a patient is type 2 diabetic, drinking habits precede the onset of diabetes.
Another important issue is that heavy drinking is a subjective phenomenon; aﬀected individuals perceive intoxication
through emotional, psychological, and mood-oriented symptoms. Occasionally, it may be associated with the reactions
their bodies exhibit such as headaches, vomiting, or palpitations. Unfortunately, individuals themselves or even diagnostic measures would miss important components that
underlie changes in metabolism, cell signaling, and ultimately
their pathogenesis. Therefore, the ﬁrst important step is identifying and validating reliable biomarkers based on the progressive changes in metabolism, cell signaling, and
pathophysiology pertaining to double trouble.

Fig. 2. Exacerbation of aldehyde stress in diabetics with alcohol toxicity. Diabetes-induced hyperglycemia-mediated reactive oxygen species (ROS)
generates reactive aldehydes like 4-hydroxy-2-nonenal (4HNE). ROS and 4HNE decrease aldehyde dehydrogenase 2 (ALDH2) activity. Increased alcohol consumption result in excessive acetaldehyde levels and reduced ALDH2 activity. All of these changes lead to aldehydic stress, cellular dysfunction,
and organ damage.
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DEVELOPMENT OF NEW THERAPEUTIC TARGETS
The novel possible therapeutic targets should be the converging point between diabetes-induced toxicity and alcoholinduced toxicity at the metabolic, cell signaling, and pathophysiological levels (Fig. 2). For instance, we propose the
axis of accumulation of reactive aldehydes (metabolic
changes), inhibition of ALDH2 activity (cellular signaling),
and mitochondrial dysfunction (pathophysiological changes)
as the possible therapeutic targets. Reactive aldehydes are
generated as a result of changes in metabolism of alcohol
and high glucose-induced oxidative stress. Furthermore,
ALDH2 activity inﬂuences the level of aldehydes in both
conditions. This central problem lies in the fact that reactive
aldehydes are known to induce mitochondrial dysfunction in
both diabetes and alcohol toxicity. We call for new research
initiatives to focus on the pathogenesis of the disease at multiple levels.
In conclusion, it is important to recognize the magnitude
of “double trouble” epidemically as rates of both diabetes
and alcohol toxicity are climbing. We described possible
challenges in diagnosis, treatment, and management of the
condition. Finally, we proposed potential strategy for identifying therapeutic targets.
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